The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
The company's need to find another growth story is laid bare by a setback to its label expansion plans for Cabometyx.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.